Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the rapid expansion is under scrutiny amid cost pressures, and the new CEO is looking for cost cuts.  Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the rapid expansion is under scrutiny amid cost pressures, and the new CEO is looking for cost cuts. 
